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Abstract
Candida spp. are responsible for severe infections in immunocompromised patients and those undergoing invasive procedures. The accurate
identiﬁcation of Candida species is important because emerging species can be associated with various antifungal susceptibility spectra.
Conventional methods have been developed to identify the most common pathogens, but have often failed to identify uncommon species.
Several studies have reported the efﬁciency of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF
MS) for the identiﬁcation of clinically relevant Candida species. In this study, we evaluated two commercially available MALDI-TOF systems,
AndromasTM and Bruker BiotyperTM, for Candida identiﬁcation in routine diagnosis. For this purpose, we investigated 1383 Candida isolates
prospectively collected in eight hospital laboratories during routine practice. MALDI-TOF MS results were compared with those obtained
using conventional phenotypic methods. Analysis of rDNA gene sequences with internal transcribed regions or D1-D2 regions is considered
the reference standard for identiﬁcation. Both MALDI-TOF MS systems could accurately identify 98.3% of the isolates at the species level
(1359/1383 for AndromasTM; 1360/1383 for Bruker BiotyperTM) vs. 96.5% for conventional techniques. Furthermore, whereas conventional
methods failed to identify rare or emerging species, these were correctly identiﬁed by MALDI-TOF MS. Both MALDI-TOF MS systems are
accurate and cost-effective alternatives to conventional methods for mycological identiﬁcation of clinically relevant Candida species and
should improve the diagnosis of fungal infections as well as patient management.
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Introduction
Candida yeasts are responsible for frequent and severe
infectious complications in immunocompromised patients
and those undergoing invasive procedures [1]. While six
species of Candida (i.e. Candida albicans, Candida tropicalis,
Candida glabrata, Candida parapsilosis, Candida kefyr and Candida
krusei) are currently considered the leading aetiological agents
of candidiasis, several other Candida species have been
reported as signiﬁcant pathogens [2]. At present, up to 40
distinct Candida species have been shown to infect humans [3].
Identiﬁcation of these new clinically relevant species has been
made possible due to the development of molecular identiﬁ-
cation [4–6]. An accurate identiﬁcation of Candida species is of
major importance, as several of these emerging species have
distinct antifungal susceptibility proﬁles and/or could be
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE MYCOLOGY
associated with speciﬁc clinical settings [7]. Conventional
methods routinely used in a mycology laboratory for identi-
ﬁcation of yeasts traditionally included a combination of
phenotypic methods, including morphological and biochemical
features. However, these methods have been developed to
identify only the most common pathogens and often failed to
identify emerging/cryptic species.
Indeed, molecular taxonomic studies have revealed several
new Candida species among phenotypically distinct species
[8–10]. For instance, recent studies have revealed that some
clinical isolates previously identiﬁed as C. glabrata using
conventional methods actually belong to the closely related
species Candida nivariensis and Candida bracarensis [5]. Similarly,
some isolates formerly misidentiﬁed as C. parapsilosis actually
represent isolates of Candida metapsilosis, Candida orthopsilosis
or Lodderomyces elongisporus [9,10]. Molecular identiﬁcation, by
sequencing genomic regions of the rDNA genes, is considered
the ‘reference standard’ for accurate identiﬁcation of Candida
at the species level [4–6]. However, sequencing of clinical
isolates is still time-consuming and not standardized; it cannot
therefore be used as a routine method for yeast identiﬁcation.
In recent years, several studies have reported the perfor-
mance of matrix-assisted laser desorption ionization-time of
ﬂightmass spectrometry (MALDI-TOFMS) for the identiﬁcation
of clinically relevant Candida species [11–14]. This method could
represent a valid and rapid alternative to both conventional and
molecular methods for yeast identiﬁcation in routine practice.
Currently, there are four commercial systems available: the
MALDI Biotyper (Bruker Daltonics, Bremen, Germany), the
AXIMA@SARAMIS database (AnagnosTec, Potsdam, Germany
and Shimadzu, Duisburg, Germany), and lately the Andromas
(Andromas, Paris, France) and VITEK MS systems (bioMerieux,
Marcy l’Etoile, France)[15]. However, this method has not yet
been comparatively evaluated in a large number of clinical
isolates concomitantly with accepted standards.
In this study, we compared the identiﬁcation efﬁciency of
two MALDI-TOF MS systems, AndromasTM and Bruker Maldi
BiotyperTM, with that of conventional methods on a large panel
of 1383 clinical isolates of Candida obtained from eight French
university hospital laboratories. Our results demonstrate that
both techniques are reliable, the AndromasTM strategy being
easier to perform in clinical microbiology laboratories as it
does not require protein extraction.
Materials and Methods
Candida isolates
The Candida isolates included in this study have been
prospectively isolated over a 2-month period from patients
hospitalized in haematology, intensive care and renal transplant
units of eight French university hospitals. All isolates, from
both superﬁcial and deep sites, were collected by the
laboratories in sequential order without any selection criteria.
Isolates were cultured on chromogenic media (CHROMagar
CandidaTM medium (Becton-Dickinson, Le Pont-de-Claix,
France)) for 48 h at 35°C. Growing colonies were checked
for mixed cultures and transferred to a new plate. The isolates
growing in pure culture were identiﬁed routinely in each of the
eight laboratories by conventional methods using the same
protocol of identiﬁcation described below. The isolates were
cryopreserved at 80°C until use. In total, 1383 Candida
isolates have been included.
Conventional methods
Isolates identiﬁed as C. albicans on CHROMagar CandidaTM
media were screened with the Bichro-DubliTM test (Soﬁbel,
Levallois-Perret, France) to identify C. dubliniensis [10–12].
Isolates suspected to be C. glabrata or C. krusei were tested
using the RTT GlabrataTM (Soﬁbel) and Krusei-colorTM (Soﬁbel)
methods, respectively [10,13]. All other isolates were identi-
ﬁed using ID32C AUXTM identiﬁcation strips (bioMerieux),
according to the manufacturer’s instructions. We deﬁned an
identiﬁcation score of  98% by the ID32C AUXTM method as
the threshold for accurate identiﬁcation at the species level.
MALDI-TOF MS
The 1383 isolates were identiﬁed blindly by the two
MALDI-TOF systems in two independent laboratories.
Analysis by the MALDI-TOF AndromasTM system
Part of a pure colony of each pure culture was transferred to
an AndromasTM target well using a disposable loop, overlaid
with 1 lL of formic acid 70% (v/v) and dried. One microlitre of
a saturated solution of a-cyano-4-hydroxycinnamic acid, 50%
acetonitrile and 2.5% triﬂuoroacetic acid (HCCA; matrix
solution) was then added and allowed to co-crystallize with the
sample. Samples were processed in a MALDI-TOF spectrom-
eter (AndromasTM, Paris, France) with the control software
[12,16–18]. Positive ions were extracted with an accelerating
voltage of 20 kV in linear mode. The spectra were analysed
and compared in an m/z range of 3000–20 000 Da with
Andromas software (AndromasTM). The Andromas software
identiﬁed the number of common peaks between the spectra
of the tested isolate and the species-speciﬁc spectral ﬁnger-
prints of the reference strains in the database. Brieﬂy, for each
isolate, all peaks with an intensity >0.1 were retained and were
compared with the peaks for the species-speciﬁc spectral
ﬁngerprints of each reference strain, taking into account
possible variations in the m/z value of 10. Subsequently, the
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percentage of common peaks was obtained using the formula:
100 9 (number of common peaks between the tested isolate
and the species-speciﬁc spectral ﬁngerprint/total number of
peaks speciﬁc to the species-speciﬁc spectral ﬁngerprint). An
acceptable identiﬁcation was given if the percentage of
common peak was  70% of those of a species-speciﬁc proﬁle
in the database. A 10% difference between the ﬁrst two
species diagnostics having the best match in the database is
also required to give species identiﬁcation.
Analysis by the MALDI-TOF BiotyperTM system
Samples were prepared according to the manufacturer’s
instructions. Brieﬂy, two to three yeast colonies were
transferred using a 10-lL inoculating loop into 300 lL of
distilled water and 900 lL of ethanol (Sigma-Aldrich, St Louis,
MO, USA). The suspension was pelleted after centrifugation
at 6000 g for 3 min, dried, and reconstituted in 50 lL of 70%
formic acid (Sigma-Aldrich). After incubation for 30 min,
50 lL of acetonitrile (Sigma-Aldrich) was added. The sus-
pension was then centrifuged at 6000 g for 3 min. A volume
of 1.5 lL of the supernatant was applied to a 96-spot
AnchorchipTM target (Bruker Daltonics, Inc., Bremen, Ger-
many) plate and dried. A saturated solution of 1.8 lL of
MALDI matrix (HCCA; Bruker Daltonics, Inc., Bremen,
Germany) was applied to the fungal smear and dried.
Measurements were performed with a MicroﬂexTM mass
spectrometer (Bruker Daltonics, Wissembourg, France) using
the FlexControlTM software (version 3.3.108.0). Mass spectra
ranging from 2000 to 20 000 Da were acquired in a linear,
extraction mode with positive polarity. The spectrum was
imported into the Biotyper software (version 3.0; Bruker,
Karlsruhe, Germany). The generated spectrum of biomarkers
for each sample was then compared with reference spectra in
the Bruker library. Identiﬁcations from MALDI-TOF were
classiﬁed using modiﬁed score values proposed by the
manufacturer: a score  2 indicated identiﬁcation to the
species level; a score between 1.7 and 1.99 indicated
identiﬁcation to the genus level; and a score of <1.7 indicated
no identiﬁcation.
Molecular identiﬁcation
Molecular identiﬁcation of isolates was performed by ampli-
ﬁcation and sequencing of the ITS rDNA regions without
a prior DNA extraction step (colony-PCR), as previously
described [19]. Ampliﬁcation of the ITS rDNA was achieved
using the universal primers ITS1 (TCCGTAGGTGAACC
TGCGG) and ITS4 (TCCTCCGCTTATTGATATGC) [20].
Nucleotide sequences were assembled using Seqscape soft-
ware (Applied Biosystems, Foster City, CA, USA.). Molecular
identiﬁcation was achieved by comparing sequence data with
the GenBank database using the BLAST algorithm (http://blast.
ncbi.nlm.nih.gov/Blast.cgi) or with the MycoBank database
(http://www.cbs.knaw.nl/collections/BioloMICSSequences.aspx).
For some isolates, identiﬁcation was also conﬁrmed by
ampliﬁcation of the D1-D2 region of the 28S rDNA using
NL1 (GCATATCAATAAGCGGAGGAAAAG) and NL4
(GGTCCGTGTTTCAAGACGG) primers [20]. A per cent
similarity of  98% between the unknown sequence and the
closest matching sequence from the reference database
was used as the criterion to classify an isolate to the species
level.
Criteria for ﬁnal species identiﬁcation of isolates
All isolates were subjected to conventional identiﬁcation
methods, andMALDI-TOFAndromasTM and BiotyperTM systems.
The ﬁnal species identiﬁcation of isolates was performed as
follows: an accurate identiﬁcation of the species C. albicans,
C. dubliniensis, C. krusei and C. tropicalis was conﬁrmed if the
three methods (conventional methods, and AndromasTM and
BiotyperTM MALDI-TOF systems) yielded the same species
identiﬁcation. When discrepant results were observed for the
three methods or when only two out of three methods yielded
identiﬁcation, ITS rDNA and/or D1-D2 sequencing was
performed and was considered as the ﬁnal species identiﬁca-
tion. For the remaining Candida species, the ﬁnal identiﬁcation
of isolates was by molecular identiﬁcation, regardless of the
results obtained by the three methods.
Results
Final species identiﬁcation of isolates
We analysed 1383 isolates obtained from the eight diagnostic
laboratories during routine practice. For 950 isolates (68.7%),
the use of conventional methods and the two MALDI-TOF
systems resulted in the accurate identiﬁcation of 836 isolates
of C. albicans, 31 of C. dubliniensis, 44 of C. krusei and 39 of
C. tropicalis. For the 433 (31.3%) remaining isolates, ﬁnal
identiﬁcation was obtained by rDNA sequencing. In all, ﬁnal
identiﬁcation at the species level was obtained for all the 1383
isolates that encompassed 20 Candida species (Table 1).
Performance of each identiﬁcation method
Biochemical methods could accurately identify 1336 of the
isolates (96.5%). Forty-four isolates (3.5%) were misidentiﬁed
and three isolates were not identiﬁed (two C. albicans and one
C. bracarensis). Isolates belonging to the species complexes
were misidentiﬁed or not identiﬁed by conventional biochem-
ical methods. Similarly, none of the uncommon species,
C. fabianii (n = 17), C. sphaerica (n = 1), C. fermentati (n = 3)
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and C. ethanolica (n = 1), was identiﬁed correctly by biochem-
ical methods.
The MALDI-TOF MS AndromasTM system was able to
accurately identify 1359 isolates (98.2%). Three isolates
(0.24%) were misidentiﬁed: one C. parapsilosis instead of a
C. glabrata, one C. albicans instead of a C. fermentati, and one
C. guilliermondii instead of a C. ethanolica. Twenty-one isolates
belonging to four species were not identiﬁed because these
species were not included in the database (C. fabianii and
C. magnoliae) or because of no spectral acquisition (one
C. dubliniensis and two C. fermentati).
The MALDI-TOF MS BioTyperTM system could accurately
identify 1360 isolates (98.2%). Five isolates (0.36%) were
misidentiﬁed: two C. parapsilosis instead of C. fabianii, one
C. albicans instead of C. fabianii, one C. kefyr instead of
C. fabianii, and one C. guilliermondii instead of C. fermentati.
Eighteen isolates belonging to ﬁve species could not be
identiﬁed because these species were not included in the
database (C. bracarensis, C. sphaerica, C. ethanolica, C. fermen-
tati and C. fabianii).
Discrepancies and errors in the three systems of identiﬁ-
cation (biochemical methods, and AndromasTM and Biotyper
MALDI-TOF MS systemsTM) are given in Table 1.
Discussion
This study shows that the MALDI-TOF MS AndromasTM and
BiotyperTM systems appear to be fast and powerful techniques
for the accurate identiﬁcation of Candida species routinely
isolated in medical laboratories, both providing a high rate of
correct identiﬁcation at the Candida species level (98.2% each).
Both MALDI-TOF systems appear more reliable than the
conventional phenotypic methods that are used routinely
(96.5% of correct identiﬁcation). These ﬁndings are in
accordance with recent studies showing comparable results,
with yeast identiﬁcation rates of 97.6% with Biotyper 2.0 and
96.1% with Saramis MALDI-TOF systems [11,21].
Importantly, we demonstrated an excellent agreement
between identiﬁcations by MALDI-TOF MS and those pro-
vided by rDNA sequencing. Indeed, only three (0.7%) and ﬁve
(1.1%) isolates of the 433 requiring molecular identiﬁcation
were misidentiﬁed, respectively, by MALDI-TOF MS Andro-
masTM and BiotyperTM systems, while 44 (10.2%) misidentiﬁca-
tions were obtained using conventional methods. Unlike
previous studies, in which molecular identiﬁcation was per-
formed only when discrepant results were noted between the
compared methods [11,21], all identiﬁcations at the species
level (except for C. albicans, C. dubliniensis, C. krusei and
C. tropicalis with an ID32C score of  98%) have been
conﬁrmed by molecular methods in the present study.
Therefore, our results strongly highlight the accuracy of two
MALDI-TOF systems for Candida species identiﬁcation. Addi-
tionally, the two MALDI-TOF MS systems were able to
discriminate isolates belonging to species complexes at the
species level. However, most of the rare Candida species were
not identiﬁed using MALDI-TOF MS. Indeed, speciﬁc spectra
were not included in the databases at the time of our study.
TABLE 1. Discrepancies and errors in conventional methods and MALDI TOF MS systems (AndromasTM and Bruker BiotyperTM)
for identiﬁcation of Candida species
Final identiﬁcation
No. of isolates
Conventional identiﬁcation
MALDI-TOF identiﬁcation
AndromasTM BiotyperTM
No identiﬁcation Misidentiﬁcation No identiﬁcation Misidentiﬁcation No identiﬁcation Misidentiﬁcation
C. albicans (n = 838) 2 0 0 0 0 0
C. dubliniensis (n = 32) 0 0 1 0 0 0
C. glabrata (n = 176) 0 0 0 1 0 0
C. bracarensis (n = 1) 1 0 0 0 1 0
C. tropicalis (n = 81) 0 1 0 0 0 0
C. parapsilosis (n = 78) 0 3 0 0 0 0
C. orthopsilosis (n = 3) 0 3 0 0 0 0
C. krusei (n = 44) 0 0 0 0 0 0
C. kefyr (n = 60) 0 1 O 0 O 0
C. lusitaniae (n = 21) 0 4 0 0 0 0
C. inconspicua (n = 12) 0 8 0 0 0 0
C. guilliermondii (n = 9) 0 0 0 0 0 0
C. fabianii (n = 17) 0 17 17 0 13 4
C. intermedia (n = 3) 0 2 0 0 0 0
C. magnoliae (n = 1) 0 0 1 0 0 0
C. sphaerica (n = 1) 0 1 0 0 1 0
C. fermentati (n = 3) 0 3 2 1 2 1
C. ethanolica (n = 1) 0 1 0 1 1 0
C. utilis (n = 1) 0 0 0 0 0 0
C. lipolytica (n = 1) 0 0 0 0 O 0
Total (n = 1383) 3 44 21 3 18 5
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Once the spectra were included (on obtaining ﬁrm identiﬁca-
tion of these isolates by sequence analysis), subsequent
identiﬁcation of these species resulted in a perfectly matching
proﬁle.
The MALDI-TOF database can be updated when a species
is absent from the database; however, the high level of
expertise required for molecular identiﬁcation is sometimes a
pitfall. In our study, C. fabianii identiﬁcation was difﬁcult
because the genomic databases did not contain the complete
ITS region of C. fabianii as a single nucleotide sequence and
misidentiﬁcation with other yeast species (e.g. Lindnera (Pichia)
mississippiensis) could have occurred. Partial sequencing of the
EF1a gene facilitated correct identiﬁcation of this species [22].
One limitation of mycological identiﬁcation from clinical
samples is in the analysis of mixed cultures; in particular,
distinct species show similar colours when using chromogenic
media. We encountered this situation in our study in the
analysis of a mixed culture containing both C. albicans and
C. dubliniensis. This mixture could only be detected by
molecular analysis; biochemical and MALDI-TOF MS analysis
could only identify one of the two species. One improvement
that can be easily incorporated into MALDI-TOF MS would be
to screen several colonies presenting the same colour from
the same culture plate.
Notably, the two MALDI-TOF MS systems use distinct
sample preparation protocols. An initial extraction step of the
yeast is necessary for the Biotyper protocol, which is
time-consuming; however, when using the AndromasTM system,
cell lysis is performed directly on the steel plate. This difference
in the extraction steps of the two systems could clearly have an
impact on identiﬁcation speed in routine laboratory practice.
However, some studies have recently reported that spectra
obtained by on-target lysis with the Bruker system can be
sufﬁcient for identiﬁcation of yeasts [23,24].
In conclusion, the present study indicates that the MAL-
DI-TOF MS systems Andromas and Biotyper are reliable and
cost-effective techniques for the identiﬁcation of clinically
relevant Candida species. Identiﬁcation would be faster and
more precise than when using conventional non-automated
methods. Furthermore, spectral databases should be regularly
updated by suppliers to improve identiﬁcation rates. The
availability of MALDI-TOF MS in the clinical laboratory will
improve the diagnosis of fungal infections and patient manage-
ment, allowing appropriate antifungal therapy.
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